190 related articles for article (PubMed ID: 31772325)
1. FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
Annett S; Moore G; Short A; Marshall A; McCrudden C; Yakkundi A; Das S; McCluggage WG; Nelson L; Harley I; Moustafa N; Kennedy CJ; deFazio A; Brand A; Sharma R; Brennan D; O'Toole S; O'Leary J; Bates M; O'Riain C; O'Connor D; Furlong F; McCarthy H; Kissenpfennig A; McClements L; Robson T
Br J Cancer; 2020 Feb; 122(3):361-371. PubMed ID: 31772325
[TBL] [Abstract][Full Text] [Related]
2. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
[TBL] [Abstract][Full Text] [Related]
3. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T
Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069
[TBL] [Abstract][Full Text] [Related]
4. FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
Valentine A; O'Rourke M; Yakkundi A; Worthington J; Hookham M; Bicknell R; McCarthy HO; McClelland K; McCallum L; Dyer H; McKeen H; Waugh DJ; Roberts J; McGregor J; Cotton G; James I; Harrison T; Hirst DG; Robson T
Clin Cancer Res; 2011 Mar; 17(5):1044-56. PubMed ID: 21364036
[TBL] [Abstract][Full Text] [Related]
5. The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway.
Yakkundi A; McCallum L; O'Kane A; Dyer H; Worthington J; McKeen HD; McClements L; Elliott C; McCarthy HO; Hirst DG; Robson T
PLoS One; 2013; 8(2):e55075. PubMed ID: 23457460
[TBL] [Abstract][Full Text] [Related]
6. Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment.
Todd N; McNally R; Alqudah A; Jerotic D; Suvakov S; Obradovic D; Hoch D; Hombrebueno JR; Campos GL; Watson CJ; Gojnic-Dugalic M; Simic TP; Krasnodembskaya A; Desoye G; Eastwood KA; Hunter AJ; Holmes VA; McCance DR; Young IS; Grieve DJ; Kenny LC; Garovic VD; Robson T; McClements L
J Clin Endocrinol Metab; 2021 Jan; 106(1):26-41. PubMed ID: 32617576
[TBL] [Abstract][Full Text] [Related]
7. Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNA‑Meg3/miR‑421/PDGFRA axis.
Ye W; Ni Z; Yicheng S; Pan H; Huang Y; Xiong Y; Liu T
Int J Oncol; 2019 Dec; 55(6):1296-1312. PubMed ID: 31638182
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
9. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Casagrande F; Cocco E; Bellone S; Richter CE; Bellone M; Todeschini P; Siegel E; Varughese J; Arin-Silasi D; Azodi M; Rutherford TJ; Pecorelli S; Schwartz PE; Santin AD
Cancer; 2011 Dec; 117(24):5519-28. PubMed ID: 21692061
[TBL] [Abstract][Full Text] [Related]
10. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
11. Gallbladder cancer-associated fibroblasts promote vasculogenic mimicry formation and tumor growth in gallbladder cancer via upregulating the expression of NOX4, a poor prognosis factor, through IL-6-JAK-STAT3 signal pathway.
Pan MS; Wang H; Ansari KH; Li XP; Sun W; Fan YZ
J Exp Clin Cancer Res; 2020 Nov; 39(1):234. PubMed ID: 33153467
[TBL] [Abstract][Full Text] [Related]
12. Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer.
Jiang YX; Siu MK; Wang JJ; Mo XT; Leung TH; Chan DW; Cheung AN; Ngan HY; Chan KK
Br J Cancer; 2020 Jul; 123(2):275-287. PubMed ID: 32390009
[TBL] [Abstract][Full Text] [Related]
13. Metformin targets gastric cancer stem cells.
Courtois S; Durán RV; Giraud J; Sifré E; Izotte J; Mégraud F; Lehours P; Varon C; Bessède E
Eur J Cancer; 2017 Oct; 84():193-201. PubMed ID: 28822889
[TBL] [Abstract][Full Text] [Related]
14. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
Lo CW; Chen MW; Hsiao M; Wang S; Chen CA; Hsiao SM; Chang JS; Lai TC; Rose-John S; Kuo ML; Wei LH
Cancer Res; 2011 Jan; 71(2):424-34. PubMed ID: 21123455
[TBL] [Abstract][Full Text] [Related]
15. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ
Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635
[TBL] [Abstract][Full Text] [Related]
16. FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.
Yakkundi A; Bennett R; Hernández-Negrete I; Delalande JM; Hanna M; Lyubomska O; Arthur K; Short A; McKeen H; Nelson L; McCrudden CM; McNally R; McClements L; McCarthy HO; Burns AJ; Bicknell R; Kissenpfennig A; Robson T
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):845-54. PubMed ID: 25767277
[TBL] [Abstract][Full Text] [Related]
17. A novel model for evaluating therapies targeting human tumor vasculature and human cancer stem-like cells.
Burgos-Ojeda D; McLean K; Bai S; Pulaski H; Gong Y; Silva I; Skorecki K; Tzukerman M; Buckanovich RJ
Cancer Res; 2013 Jun; 73(12):3555-65. PubMed ID: 23576551
[TBL] [Abstract][Full Text] [Related]
18. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
[TBL] [Abstract][Full Text] [Related]
19. Targeting Angiogenesis: Taming the Medusa of Ovarian Cancer.
Dhani NC; Oza AM
Hematol Oncol Clin North Am; 2018 Dec; 32(6):1041-1055. PubMed ID: 30390759
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]